Oramed Pharmaceuticals Inc.

318 articles with Oramed Pharmaceuticals Inc.

• Oramed Pharmaceuticals Issues Shareholder Update - February 09, 2023

  2/9/2023

  Oramed Pharmaceuticals Inc., announced that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials.

• 

  Oramed's Insulin Capsule Fails Its First Phase III Trial

  1/12/2023

  Oramed, a clinical-stage company developing orally available versions of biologic drugs, reported disappointing news regarding its lead candidate, ORMD-0801.

• Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

  1/12/2023

  Oramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks.

• Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - January 4, 2023

  1/4/2023

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."  

• Oramed Letter to Shareholders

  12/21/2022

  Oramed Pharmaceuticals Inc. today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

• MEDICOX Signs Contract with ORAMED to Distribute Oral Insulin in South Korea

  11/18/2022

  On 14th, MEDICOX, listed on KOSDAQ, signed an exclusive distribution contract with an oral drug delivery platform developer, ORAMED Pharmaceuticals on the oral insulin license.

• Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

  11/17/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced additional positive data from its Phase 2 double-blind, fully randomized, placebo-controlled, multicenter clinical trial (ORA-D-N02) to assess the safety and efficacy of its oral insulin candidate (ORMD-0801), to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis ("NASH").

• Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

  11/14/2022

  Oramed Pharmaceuticals Inc. today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co., Ltd., an emerging biotech company with an excellent consortium of proven partnerships in the Republic of Korea.

• Oramed Reports Third Quarter 2022 Financial Results

  11/10/2022

  Oramed Pharmaceuticals Inc. today reported its financial results for the quarter ended September 30, 2022.  

• Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

  11/9/2022

  Oramed Pharmaceuticals Inc. today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes ("T2D") patients with non-alcoholic steatohepatitis ("NASH") on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.

• Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

  10/7/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.

• 

  Clinical Catch-Up: NASH, DMD Spaces Continue to Accelerate

  9/29/2022

  New data from Axcella, PepGen, Dystrogen and Galecto are showing promise in challenging diseases, including NASH, Duchenne muscular dystrophy and myelofibrosis. 
• 

  NASH Market Surges as Oramed, Akero Post Positive Data

  9/14/2022

  Oramed announced positive mid-stage data that showed its investigational drug ORMD-0801 reduced liver fat content in type 2 diabetes patients who have been diagnosed with NASH.

• Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

  9/13/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today positive Phase 2 results from its double-blind, fully randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of its oral insulin candidate (ORMD-0801).

• Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24th Annual Global Investment Conference.

• Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

  7/26/2022

  Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 50% of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).

• Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

  7/11/2022

  Oramed Pharmaceuticals Inc. announced today that it will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022.

• Oramed Letter to Shareholders - July 07, 2022

  7/7/2022

  Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

• Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

  6/1/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters , MD, to its Scientific Advisory Board.

• Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

  5/24/2022

  Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."